KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:PHI1 - NL0000009538 - Common Stock
24.21 EUR
-0.05 (-0.21%)
PHI1 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 63 industry peers in the Health Care Equipment & Supplies industry. PHI1 has a bad profitability rating. Also its financial health evaluation is rather negative. PHI1 has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PHI1 had positive earnings in the past year.
PHI1 had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
PHI1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
PHI1 has a Return On Assets of 0.61%. This is in the lower half of the industry: PHI1 underperforms 65.08% of its industry peers.
The Return On Equity of PHI1 (1.56%) is worse than 65.08% of its industry peers.
With a Return On Invested Capital value of 4.00%, PHI1 is not doing good in the industry: 60.32% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 1.56% | ||
| ROIC | 4% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Profit Margin value of 0.91%, PHI1 is not doing good in the industry: 65.08% of the companies in the same industry are doing better.
PHI1's Operating Margin of 6.11% is in line compared to the rest of the industry. PHI1 outperforms 41.27% of its industry peers.
In the last couple of years the Operating Margin of PHI1 has declined.
PHI1 has a Gross Margin of 43.85%. This is in the lower half of the industry: PHI1 underperforms 74.60% of its industry peers.
PHI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.11% | ||
| PM (TTM) | 0.91% | ||
| GM | 43.85% |
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHI1 is destroying value.
The number of shares outstanding for PHI1 has been reduced compared to 1 year ago.
PHI1 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PHI1 has a worse debt to assets ratio.
2.2 Solvency
PHI1 has an Altman-Z score of 1.94. This is not the best score and indicates that PHI1 is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.94, PHI1 is in line with its industry, outperforming 44.44% of the companies in the same industry.
The Debt to FCF ratio of PHI1 is 19.41, which is on the high side as it means it would take PHI1, 19.41 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of PHI1 (19.41) is comparable to the rest of the industry.
PHI1 has a Debt/Equity ratio of 0.69. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.69, PHI1 is not doing good in the industry: 74.60% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 19.41 | ||
| Altman-Z | 1.94 |
ROIC/WACC0.62
WACC6.5%
2.3 Liquidity
PHI1 has a Current Ratio of 1.26. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
PHI1's Current ratio of 1.26 is on the low side compared to the rest of the industry. PHI1 is outperformed by 68.25% of its industry peers.
A Quick Ratio of 0.81 indicates that PHI1 may have some problems paying its short term obligations.
PHI1 has a worse Quick ratio (0.81) than 69.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.81 |
3. Growth
3.1 Past
PHI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.15%, which is quite good.
PHI1 shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.17% yearly.
PHI1 shows a decrease in Revenue. In the last year, the revenue decreased by -0.81%.
Measured over the past years, PHI1 shows a small growth in Revenue. The Revenue has been growing by 1.00% on average per year.
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
Revenue 1Y (TTM)-0.81%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%
3.2 Future
The Earnings Per Share is expected to grow by 12.68% on average over the next years. This is quite good.
Based on estimates for the next years, PHI1 will show a small growth in Revenue. The Revenue will grow by 3.65% on average per year.
EPS Next Y0.24%
EPS Next 2Y5.1%
EPS Next 3Y7.59%
EPS Next 5Y12.68%
Revenue Next Year-1.93%
Revenue Next 2Y0.54%
Revenue Next 3Y1.79%
Revenue Next 5Y3.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.36, the valuation of PHI1 can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of PHI1 indicates a rather cheap valuation: PHI1 is cheaper than 90.48% of the companies listed in the same industry.
PHI1's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.31.
PHI1 is valuated correctly with a Price/Forward Earnings ratio of 15.82.
Based on the Price/Forward Earnings ratio, PHI1 is valued a bit cheaper than 71.43% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.59, PHI1 is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.36 | ||
| Fwd PE | 15.82 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHI1 indicates a somewhat cheap valuation: PHI1 is cheaper than 73.02% of the companies listed in the same industry.
PHI1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.72 | ||
| EV/EBITDA | 12.56 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHI1 does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)68.85
PEG (5Y)N/A
EPS Next 2Y5.1%
EPS Next 3Y7.59%
5. Dividend
5.1 Amount
PHI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:PHI1 (11/28/2025, 7:00:00 PM)
24.21
-0.05 (-0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners47.54%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap23.31B
Revenue(TTM)18.02B
Net Income(TTM)162.00M
Analysts74.81
Price Target27.65 (14.21%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP0.62%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.64%
Min EPS beat(2)22.24%
Max EPS beat(2)31.04%
EPS beat(4)2
Avg EPS beat(4)6.19%
Min EPS beat(4)-16.56%
Max EPS beat(4)31.04%
EPS beat(8)3
Avg EPS beat(8)-1.09%
EPS beat(12)5
Avg EPS beat(12)15.29%
EPS beat(16)5
Avg EPS beat(16)3.51%
Revenue beat(2)0
Avg Revenue beat(2)-1.96%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.96%
Revenue beat(4)0
Avg Revenue beat(4)-3.05%
Min Revenue beat(4)-5.22%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.22%
Revenue beat(12)2
Avg Revenue beat(12)-1.61%
Revenue beat(16)2
Avg Revenue beat(16)-1.84%
PT rev (1m)1.37%
PT rev (3m)0.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.89%
EPS NY rev (1m)-0.18%
EPS NY rev (3m)-0.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.36%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)-0.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.36 | ||
| Fwd PE | 15.82 | ||
| P/S | 1.31 | ||
| P/FCF | 53.72 | ||
| P/OCF | 21.21 | ||
| P/B | 2.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.56 |
EPS(TTM)1.48
EY6.11%
EPS(NY)1.53
Fwd EY6.32%
FCF(TTM)0.45
FCFY1.86%
OCF(TTM)1.14
OCFY4.71%
SpS18.54
BVpS10.78
TBVpS-1.76
PEG (NY)68.85
PEG (5Y)N/A
Graham Number18.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 1.56% | ||
| ROCE | 5.69% | ||
| ROIC | 4% | ||
| ROICexc | 4.43% | ||
| ROICexgc | 14.55% | ||
| OM | 6.11% | ||
| PM (TTM) | 0.91% | ||
| GM | 43.85% | ||
| FCFM | 2.43% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y10.6%
ROICexgc growth 5Y-2.51%
ROICexc growth 3Y4.73%
ROICexc growth 5Y-6.98%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-Score8
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 19.41 | ||
| Debt/EBITDA | 3.01 | ||
| Cap/Depr | 51.35% | ||
| Cap/Sales | 3.72% | ||
| Interest Coverage | 4 | ||
| Cash Conversion | 46.06% | ||
| Profit Quality | 267.9% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.81 | ||
| Altman-Z | 1.94 |
F-Score8
WACC6.5%
ROIC/WACC0.62
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
EPS Next Y0.24%
EPS Next 2Y5.1%
EPS Next 3Y7.59%
EPS Next 5Y12.68%
Revenue 1Y (TTM)-0.81%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%
Revenue Next Year-1.93%
Revenue Next 2Y0.54%
Revenue Next 3Y1.79%
Revenue Next 5Y3.65%
EBIT growth 1Y476.21%
EBIT growth 3Y0.03%
EBIT growth 5Y-7.17%
EBIT Next Year48.14%
EBIT Next 3Y21.01%
EBIT Next 5YN/A
FCF growth 1Y3516.67%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y43.47%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%
KONINKLIJKE PHILIPS NV / PHI1.DE FAQ
What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.
What is the valuation status of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for KONINKLIJKE PHILIPS NV?
KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 2 / 10.
How financially healthy is KONINKLIJKE PHILIPS NV?
The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 2 / 10.
What is the earnings growth outlook for KONINKLIJKE PHILIPS NV?
The Earnings per Share (EPS) of KONINKLIJKE PHILIPS NV (PHI1.DE) is expected to grow by 0.24% in the next year.